Expertise in
24
conditions

Dr. Paul J. Shaughnessy

Hematology
Methodist Physicians Texas Transplant Specialists-Adult Blood Marrow Transplant
Dr 1st Floor, 
Brevard, NC 
Accepting New Patients
31 Years of Experience
Expertise in
24
conditions
Methodist Physicians Texas Transplant Specialists-Adult Blood Marrow Transplant
Dr 1st Floor, 
Brevard, NC 

Overview

Paul Shaughnessy is a Hematologist practicing medicine in Brevard, North Carolina. He has been practicing medicine for over 31 years.

Dr. Shaughnessy is highly rated in 24 conditions, according to our data. His clinical expertise encompasses Acute Lymphoblastic Leukemia (ALL), Non-Hodgkin Lymphoma, Multiple Myeloma, Bone Marrow Transplant, and Bone Marrow Aspiration.

He is actively involved in clinical research, co-authoring 49 peer reviewed articles and participating in 9 clinical trials. Dr. Shaughnessy is currently accepting new patients.

Specialties

Hematology

Licenses

Internal Medicine in TX

Hospital Affiliations

Methodist Hospital
UT Health San Antonio Multispecialty & Research Ho

Languages Spoken

English
Spanish

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Community First Health Plans
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
Friday Health

Accepted plan types not found. Please verify directly with the provider.

Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Oscar
  • EPO
  • HMO
  • PPO
Superior Health Plan
  • MANAGED MEDICAID PLAN
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 9 Less Insurance Carriers -

Locations

Methodist Physicians Texas Transplant Specialists-Adult Blood Marrow Transplant
Dr 1st Floor, Brevard, NC 28712

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials

Tisagenlecleucel Versus Standard of Care in Adult Patients With Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma: A Randomized, Open Label, Phase III Trial (BELINDA)
Tisagenlecleucel Versus Standard of Care in Adult Patients With Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma: A Randomized, Open Label, Phase III Trial (BELINDA)
Enrollment Status: Completed
Publish Date: June 12, 2026
Intervention Type: Drug
Study Drugs: Tisagenlecleucel, Platinum-based immunochemotherapy, high dose chemotherapy
Study Phase: Phase 3
Managed Access Programs for CTL019, Tisagenlecleucel
Managed Access Programs for CTL019, Tisagenlecleucel
Enrollment Status: Available
Publish Date: April 23, 2026
Intervention Type: Biological
An Open-Label, Multi-Centre, Phase Ib/II Study Evaluating the Safety and Efficacy of AUTO1, a CAR T Cell Treatment Targeting CD19, in Adult Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukaemia
An Open-Label, Multi-Centre, Phase Ib/II Study Evaluating the Safety and Efficacy of AUTO1, a CAR T Cell Treatment Targeting CD19, in Adult Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukaemia
Enrollment Status: Active_not_recruiting
Publish Date: April 08, 2026
Intervention Type: Biological
Study Drugs: Cyclophosphamide, Fludarabine, CD19-Positive CAR-T Cells
Study Phase: Phase 1/Phase 2
A Multi-center Randomized Phase II Study of the Impact of CD34+ Cell Dose on Absolute Lymphocyte Count Following High-Dose Therapy and Autologous Stem Cell Transplantation for Relapsed and Refractory Diffuse Large B-cell Lymphoma (DLBCL)
A Multi-center Randomized Phase II Study of the Impact of CD34+ Cell Dose on Absolute Lymphocyte Count Following High-Dose Therapy and Autologous Stem Cell Transplantation for Relapsed and Refractory Diffuse Large B-cell Lymphoma (DLBCL)
Enrollment Status: Active_not_recruiting
Publish Date: November 26, 2025
Intervention Type: Procedure, Drug
Study Drugs: Plerixafor, carmustine, etoposide, cytarabine, melphalan
Study Phase: Phase 2
A Safety Trial of Lisocabtagene Maraleucel (JCAR017) for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL) in the Outpatient Setting
A Safety Trial of Lisocabtagene Maraleucel (JCAR017) for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL) in the Outpatient Setting
Enrollment Status: Completed
Publish Date: February 27, 2025
Intervention Type: Biological
Study Drug: lisocabtagene maraleucel
Study Phase: Phase 2
A Phase 1/2 Multicenter Study Evaluating the Safety and Efficacy of KTE-C19 in Adults With Refractory Aggressive Non-Hodgkin Lymphoma
A Phase 1/2 Multicenter Study Evaluating the Safety and Efficacy of KTE-C19 in Adults With Refractory Aggressive Non-Hodgkin Lymphoma
Enrollment Status: Completed
Publish Date: June 04, 2024
Intervention Type: Biological, Drug
Study Drugs: Axicabtagene Ciloleucel, Fludarabine, Cyclophosphamide
Study Phase: Phase 1/Phase 2
Protocol H125001: An Open-Label Phase 1/2 Study of JCARH125, BCMA-targeted Chimeric Antigen Receptor (CAR) T Cells, in Subjects With Relapsed or Refractory Multiple Myeloma
Protocol H125001: An Open-Label Phase 1/2 Study of JCARH125, BCMA-targeted Chimeric Antigen Receptor (CAR) T Cells, in Subjects With Relapsed or Refractory Multiple Myeloma
Enrollment Status: Completed
Publish Date: May 24, 2024
Intervention Type: Biological
Study Drugs: JCARH125, JCARH125 + Anakinra
Study Phase: Phase 1/Phase 2
A Randomized Phase II/III Study of αβ T Cell-Depleted, Related, Haploidentical Hematopoietic Stem Cell Transplant (Haplo-HSCT) Plus Rivogenlecleucel vs. Haplo-HSCT Plus Post-Transplant Cyclophosphamide (PTCy) in Patients With AML or MDS
A Randomized Phase II/III Study of αβ T Cell-Depleted, Related, Haploidentical Hematopoietic Stem Cell Transplant (Haplo-HSCT) Plus Rivogenlecleucel vs. Haplo-HSCT Plus Post-Transplant Cyclophosphamide (PTCy) in Patients With AML or MDS
Enrollment Status: Terminated
Publish Date: September 29, 2023
Intervention Type: Biological, Drug, Procedure
Study Phase: Phase 2/Phase 3
A Phase 3, Multicenter, Randomized, Double-blind, Double-dummy, Active-controlled Study to Assess the Efficacy and Safety of Maribavir Compared to Valganciclovir for the Treatment of Cytomegalovirus (CMV) Infection in Hematopoietic Stem Cell Transplant Recipients
A Phase 3, Multicenter, Randomized, Double-blind, Double-dummy, Active-controlled Study to Assess the Efficacy and Safety of Maribavir Compared to Valganciclovir for the Treatment of Cytomegalovirus (CMV) Infection in Hematopoietic Stem Cell Transplant Recipients
Enrollment Status: Completed
Publish Date: March 03, 2023
Intervention Type: Drug, Other
Study Phase: Phase 3
View 8 Less Clinical Trials

49 Total Publications

Erratum to: "Tumor burden-guided dosing contributes to mitigation of immunotoxicities following treatment with obecabtagene autoleucel in adult patients with relapsed/ refractory B-cell acute lymphoblastic leukemia".
Erratum to: "Tumor burden-guided dosing contributes to mitigation of immunotoxicities following treatment with obecabtagene autoleucel in adult patients with relapsed/ refractory B-cell acute lymphoblastic leukemia".
Journal: Haematologica
Published: August 01, 2026
Similar Doctors
Expertise in
33
conditions
Dr. Jeffrey K. Giguere
Hematology | Oncology
Expertise in
33
conditions
Dr. Jeffrey K. Giguere
Hematology | Oncology
Referral may be required

Office

300 E McBee Ave, 
Greenville, SC 
 (30.8 miles away)
864-699-5700
Languages Spoken:
English

Jeffrey Giguere is a Hematologist and an Oncologist practicing medicine in Greenville, South Carolina. Dr. Giguere is highly rated in 33 conditions, according to our data. His clinical expertise encompasses Breast Cancer, Myelodysplastic Syndrome (MDS), Lung Cancer, Colorectal Cancer, and Bone Marrow Aspiration.

Expertise in
67
conditions
Dr. Michael S. Humeniuk
Hematology | Oncology
Expertise in
67
conditions
Dr. Michael S. Humeniuk
Hematology | Oncology
Referral may be required

SMc-Center For Hematology/Oncology-Pelham

2759 S Highway 14, 
Greer, SC 
 (37.8 miles away)
864-849-9700
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Michael Humeniuk is a Hematologist and an Oncologist practicing medicine in Greer, South Carolina. Dr. Humeniuk is highly rated in 67 conditions, according to our data. His clinical expertise encompasses Lung Cancer, Prostate Cancer, Pleuropulmonary Blastoma, Urothelial Cancer, and Endoscopy. Dr. Humeniuk is currently accepting new patients.

Expertise in
31
conditions
Dr. Mark A. O'rourke
Hematology | Oncology
Expertise in
31
conditions
Dr. Mark A. O'rourke
Hematology | Oncology
Referral may be required

Prisma Health-Upstate

65 International Dr, 
Greenville, SC 
 (33.9 miles away)
864-987-7000
Languages Spoken:
English
See accepted insurances

Mark O'rourke is a Hematologist and an Oncologist practicing medicine in Greenville, South Carolina. Dr. O'rourke is highly rated in 31 conditions, according to our data. His clinical expertise encompasses Colorectal Cancer, Pancreatic Cancer, Familial Pancreatic Cancer, and Undifferentiated Pleomorphic Sarcoma.

Frequently Asked Questions about Dr. Paul J. Shaughnessy

How do I make an appointment with Dr. Paul J. Shaughnessy?

You can book an appointment with Dr. Paul J. Shaughnessy by calling their office at 210-575-3817. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Paul J. Shaughnessy a top-rated expert for Acute Lymphoblastic Leukemia (ALL)?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Paul J. Shaughnessy is classified as an Distinguished expert for Acute Lymphoblastic Leukemia (ALL), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Paul J. Shaughnessy specialize in?

While Dr. Paul J. Shaughnessy is a Hematology, they have specific expertise in Acute Lymphoblastic Leukemia (ALL), Bone Marrow Transplant, and Non-Hodgkin Lymphoma. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Paul J. Shaughnessy participate in research or clinical trials?

Yes. Dr. Paul J. Shaughnessy has published 49 articles and abstracts on conditions like Acute Lymphoblastic Leukemia (ALL). You can view a list of Dr. Paul J. Shaughnessy's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Paul J. Shaughnessy accept my insurance?

Dr. Paul J. Shaughnessy accepts most major insurance plans, including Aetna and Blue Cross Blue Shield. We recommend calling the office directly at 210-575-3817 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Shaughnessy's expertise for a condition
ConditionClose
    View All 8 Distinguished Conditions
    View All 16 Advanced Conditions
    View All 18 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile